PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35570320-0	2022	Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib.	tofacitinib	88-99	interferon induced with helicase C domain 1	Homo sapiens	13-17	
33769925-0	2021	Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: a literature review.	tofacitinib	0-11	interferon induced with helicase C domain 1	Homo sapiens	63-67	
34946303-0	2021	Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report.	tofacitinib	36-47	interferon induced with helicase C domain 1	Homo sapiens	142-146	
34946303-7	2021	To our knowledge, this is the first reported case of anti-MDA5-associated dermatomyositis with RP-ILD successfully treated with the combination of rituximab, tofacitinib, and pirfenidone.	tofacitinib	158-169	interferon induced with helicase C domain 1	Homo sapiens	58-62	
35570320-5	2022	CASE PRESENTATION: We report a case of anti-MDA5 antibody-positive dermatomyositis that was relieved after treatment with tofacitinib, during which gallbladder gangrene and suppurative cholecystitis occurred.	tofacitinib	122-133	interferon induced with helicase C domain 1	Homo sapiens	44-48	
35570320-7	2022	CONCLUSIONS: Tofacitinib is effective in the treatment of anti-MDA5 antibody-positive dermatomyositis, but the risk of infection is increased.	tofacitinib	13-24	interferon induced with helicase C domain 1	Homo sapiens	63-67	
32867615-0	2021	Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies.	tofacitinib	30-41	interferon induced with helicase C domain 1	Homo sapiens	113-155	
32867615-4	2021	We herein report a case of anti-MDA-5 antibody-positive dermatomyositis and associated ILD who had not responded to the triple therapy and tofacitinib 10 mg/day but markedly responded after increasing the dose of tofacitinib to 20 mg/day.	tofacitinib	139-150	interferon induced with helicase C domain 1	Homo sapiens	32-37	
32867615-4	2021	We herein report a case of anti-MDA-5 antibody-positive dermatomyositis and associated ILD who had not responded to the triple therapy and tofacitinib 10 mg/day but markedly responded after increasing the dose of tofacitinib to 20 mg/day.	tofacitinib	213-224	interferon induced with helicase C domain 1	Homo sapiens	32-37	
30614890-0	2021	Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis.	tofacitinib	125-136	interferon induced with helicase C domain 1	Homo sapiens	160-164	
32360518-0	2020	Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis.	tofacitinib	12-23	interferon induced with helicase C domain 1	Homo sapiens	96-100	
33252394-0	2021	A Case of Refractory Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis That Improved After Switching to Tofacitinib.	tofacitinib	118-129	interferon induced with helicase C domain 1	Homo sapiens	55-59	
32925726-4	2020	Recently, it has been reported that tofacitinib (TOF) could be effective for refractory anti-MDA5 Ab-positive cADM with ILD.	tofacitinib	36-47	interferon induced with helicase C domain 1	Homo sapiens	93-97	
32925726-4	2020	Recently, it has been reported that tofacitinib (TOF) could be effective for refractory anti-MDA5 Ab-positive cADM with ILD.	tofacitinib	49-52	interferon induced with helicase C domain 1	Homo sapiens	93-97	
31603183-0	2019	Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.	tofacitinib	83-94	interferon induced with helicase C domain 1	Homo sapiens	25-29	
31603187-0	2019	Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.	tofacitinib	76-87	interferon induced with helicase C domain 1	Homo sapiens	18-22	
30060040-1	2018	Objective: We aimed to determine the outcome of combination therapy with tofacitinib (TOF) in a case series of refractory rapidly progressive interstitial lung disease (ILD) associated with anti-melanoma differentiation-associated 5 gene (MDA5) antibody-positive (Ab+) DM.	tofacitinib	73-84	interferon induced with helicase C domain 1	Homo sapiens	239-243